QQQ   256.15 (-0.92%)
AAPL   380.39 (-0.40%)
MSFT   205.62 (-0.70%)
AMZN   3,023.22 (-2.60%)
TSLA   1,492.05 (-0.33%)
F   6.34 (+4.28%)
BAC   23.92 (-1.12%)
QQQ   256.15 (-0.92%)
AAPL   380.39 (-0.40%)
MSFT   205.62 (-0.70%)
AMZN   3,023.22 (-2.60%)
TSLA   1,492.05 (-0.33%)
F   6.34 (+4.28%)
BAC   23.92 (-1.12%)
QQQ   256.15 (-0.92%)
AAPL   380.39 (-0.40%)
MSFT   205.62 (-0.70%)
AMZN   3,023.22 (-2.60%)
TSLA   1,492.05 (-0.33%)
F   6.34 (+4.28%)
BAC   23.92 (-1.12%)
QQQ   256.15 (-0.92%)
AAPL   380.39 (-0.40%)
MSFT   205.62 (-0.70%)
AMZN   3,023.22 (-2.60%)
TSLA   1,492.05 (-0.33%)
F   6.34 (+4.28%)
BAC   23.92 (-1.12%)
Log in

OTCMKTS:MKKGYMERCK KGAA/S Stock Price, Forecast & News

$25.02
+0.14 (+0.56 %)
(As of 07/14/2020 01:14 PM ET)
Add
Compare
Today's Range
$24.91
Now: $25.02▼
$25.47
50-Day Range
$22.32
MA: $23.43▼
$24.88
52-Week Range
$16.55
Now: $25.02▼
$27.23
Volume21,100 shs
Average Volume109,329 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for use in the discovery, development, and manufacture of drug therapies, as well as in laboratories; and specialty chemicals for use in displays, computer chips, surfaces, Integrated circuits, microelectronic systems, anti-reflection coatings, and cosmetics. It has alliances with Pfizer Inc., Bristol-Myers Squibb Company, Intrexon Corporation, Avillion LLP., F-star Delta Ltd, SFJ Pharmaceuticals Group, Alibaba Health, Checkmate Pharmaceuticals, Solvias, and Leap Therapeutics, Inc., as well as a collaboration with Daiichi Sankyo Company, Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.48 out of 5 stars


Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MKKGY
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.merckgroup.com
Phone+49-6151-720

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees51,039
Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable
OTC:MKKGY Rates by TradingView

Receive MKKGY News and Ratings via Email

Sign-up to receive the latest news and ratings for MKKGY and its competitors with MarketBeat's FREE daily newsletter.

MERCK KGAA/S (OTCMKTS:MKKGY) Frequently Asked Questions

How has MERCK KGAA/S's stock been impacted by COVID-19 (Coronavirus)?

MERCK KGAA/S's stock was trading at $21.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MKKGY shares have increased by 13.9% and is now trading at $25.0180. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of MERCK KGAA/S?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MERCK KGAA/S in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for MERCK KGAA/S.

Has MERCK KGAA/S been receiving favorable news coverage?

News coverage about MKKGY stock has trended somewhat positive on Tuesday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MERCK KGAA/S earned a coverage optimism score of 1.8 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about MERCK KGAA/S.

Who are some of MERCK KGAA/S's key competitors?

Who are MERCK KGAA/S's key executives?

MERCK KGAA/S's management team includes the following people:
  • Dr. Stefan Oschmann, Chairman of Exec. Board & CEO (Age 62)
  • Dr. Marcus Kuhnert, CFO & Member of Exec. Board (Age 51)
  • Dr. Kai Beckmann, CEO of Performance Materials & Member of the Exec. Board (Age 54)
  • Dr. Udit Batra, CEO of Life Science & Member of Exec. Board (Age 48)
  • Ms. Belén Garijo López M.D., CEO of Healthcare & Member of the Exec. Board (Age 59)

What is MERCK KGAA/S's stock symbol?

MERCK KGAA/S trades on the OTCMKTS under the ticker symbol "MKKGY."

How do I buy shares of MERCK KGAA/S?

Shares of MKKGY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MERCK KGAA/S's stock price today?

One share of MKKGY stock can currently be purchased for approximately $25.02.

What is MERCK KGAA/S's official website?

The official website for MERCK KGAA/S is www.merckgroup.com.

How can I contact MERCK KGAA/S?

MERCK KGAA/S's mailing address is Frankfurter Strasse 250, DARMSTADT, 64293, Germany. The company can be reached via phone at +49-6151-720.

This page was last updated on 7/14/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.